natgillin/translations-raw huggingface dataset:
• increased levels of creatine phosphokinase (CPK) in blood in Japanese patients (CPK is an enzyme found mainly in skeletal muscles) 
• zvišane vrednosti kreatin-fosfokinaze (CPK) v krvi japonskih bolnikov (CPK je encim, ki ga najdemo predvsem v skeletnih mišicah)
Do not use Leganto if: 
Ne uporabljajte zdravila Leganto, če:
• increased or abnormal liver function test results 
• povišani ali nenormalni izvidi preiskav delovanja jeter
• unusual urges or cravings which you cannot resist and that could harm yourself or others - the symptoms are mainly seen in patients with Parkinson's disease 
• nenavadne težnje ali želje, ki se jim ne morete upreti in bi lahko škodovale vam ali drugim - ti simptomi so večinoma opazni pri bolnikih s Parkinsonovo boleznijo
Two pivotal trials (SP512 Part I and SP513 Part I) investigating the effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic Parkinson's disease were conducted in patients who were not receiving concomitant dopamine agonist therapy and were either L-dopa naïve or previous L-dopa treatment was ≤ 6 months. 
Dve ključni preskušanji (SP512 del I in SP513 del I), pri katerih so preučevali učinkovitost rotigotina pri zdravljenju znakov in simptomov idiopatične Parkinsonove bolezni, so opravili na bolnikih, ki niso prejemali sočasnega zdravljenja z agonistom dopamina in ki bodisi niso nikoli prejemali L-dope ali katerih predhodno zdravljenje z L-dopo je trajalo ≤ 6 mesecev.
Application site reactions 
Reakcije na mestu aplikacije
Rotigotine did not influence male fertility in rats, but clearly reduced female fertility in rats and mice, because of the effects on prolactin levels which are particularly significant in rodents. 
Rotigotin ni vplival na plodnost podganjih samcev, vendar je očitno zmanjšal plodnost samic podgan in miši zaradi učinka na raven prolaktina, ki je pri glodavcih posebno pomembna.
The difference was 5.28 points and statistically significant (p<0.0001). 
Razlika je bila 5,28 točke in je bila statistično pomembna (p<0,0001).
If you stop using Leganto 
Če ste prenehali uporabljati zdravilo Leganto
Limited pharmacokinetic data obtained in adolescent patients with RLS (13-17 years, n=24) following treatment with multiple doses of 0.5 to 3mg/24h showed that systemic exposure to rotigotine was similar to that observed in adults. 
Omejeni podatki o farmakokinetiki pri mladostnikih z RLS (13-17 let, n=24) pri zdravljenju z večkratnimi odmerki od 0,5 do 3 mg/24h, so pokazali podobno sistemsko izpostavljenost rotigotinu kot pri odraslih.
• strong impulse to gamble too much - even if this seriously affects you or your family 
• močna želja po pretiranem hazardiranju kljub resnim osebnim ali družinskim posledicam
Dopamine dysregulation syndrome c 
Dopaminski disregulacijski sindrom c
The patch remains on the skin for 24 hours and will then be replaced by a new one at a different site of application. 
Obliž ostane na koži 24 ur, nato ga nadomestimo z novim, za katerega izberemo drugo mesto namestitve.
Abnormal thinking and behaviour 
Nenormalno mišljenje in vedenje
Dialysis would not be expected to be beneficial as rotigotine is not eliminated by dialysis. 
Ni pričakovati, da bi bila dializa koristna, ker rotigotina ne moremo odstraniti z dializo.
Rotigotine is believed to elicit its beneficial effect on Parkinson's disease by activation of the D3, D2 and D1 receptors of the caudate-putamen in the brain. 
Domneva se, da rotigotin doseže zdravilni učinek na Parkinsonovo bolezen z aktivacijo receptorjev D3, D2 in D1 kavdatnega jedra ter putamena v možganih.
• you need to have a magnetic resonance imaging (MRI) scan (diagnostic pictures of the inside of the body, created using magnetic rather than x-ray energy) 
• vam bodo opravili magnetnoresonančno slikanje MRI) (diagnostična slika notranje zgradbe telesa, narejena z uporabo magnetne energije namesto energije rentgenskih žarkov)
Transdermal use 
transdermalna uporaba
• Change the patch at about the same time every day. 
• Obliž zamenjajte vsak dan ob približno enakem času.
In a 5-year open-label treatment study, augmentation occurred in 11.9% of patients treated with the approved dosages for RLS (1-3 mg/24 h), and 5.1% were considered clinically significant. 
V 5-letni odprti študiji zdravljenja se je avgmentacija pojavila pri 11,9 % bolnikov, ki so se zdravili z odobrenimi odmerki zdravila za sindrom nemirnih nog (RLS) (1-3 mg/24 h) in pri 5,1 % bolnikov je bila ocenjena kot klinično pomembna.
6.6 Special precaution for disposal 
6.6 Posebni varnostni ukrepi za odstranjevanje
It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of orthostatic hypotension associated with dopaminergic therapy. 
Zlasti v začetku zdravljenja je zaradi splošnega tveganja za z dopaminergičnim zdravljenjem povezano ortostatsko hipotenzijo priporočeno nadzorovati krvni tlak.
You should discuss with your doctor if it is safe for you to drink alcohol while using Leganto. 
Posvetujte se z zdravnikom, če je varno, da med uporabo zdravila Leganto pijete alkohol.
Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants (e.g. benzodiazepines, antipsychotics, antidepressants) or alcohol in combination with rotigotine. 
Zaradi morebitnega aditivnega učinka je potrebna previdnost, kadar bolniki v kombinaciji z rotigotinom jemljejo sedative ali druge zaviralce centralnega živčnega sistema (npr. benzodiazepine, antipsihotike, antidepresive) ali alkohol.
Leganto is a patch that is put on the skin. 
Zdravilo Leganto je obliž, ki ga prilepite na kožo.
Rotigotine did not induce gene mutations in the Ames test, but did show effects in the in vitro Mouse Lymphoma Assay with metabolic activation and weaker effects without metabolic activation. 
Rotigotin pri Amesovem testu ni povzročil genetskih mutacij, vendar je vplival na test mišjega limfoma in vitro z metabolno aktivacijo ter imel manjši učinek brez metabolne aktivacije.
Because the patch is administered transdermally, no effect of food and gastrointestinal conditions is expected. 
Obliž se uporablja transdermalno, zato ni pričakovati učinkov hrane in prebave.
Co-administration of L-dopa and carbidopa with rotigotine had no effect on the pharmacokinetics of rotigotine, and rotigotine had no effect on the pharmacokinetics of L-dopa and carbidopa. 
Sočasna uporaba L-dope in karbidope z rotigotinom ni imela učinka na farmakokinetiko rotigotina, rotigotin pa ni imel učinka na farmakokinetiko L-dope in karbidope.
Treatment initiation pack 
Pakiranje za začetno zdravljenje
Rotigotine has been associated with somnolence including excessive daytime somnolence and sudden sleep onset episodes. 
Rotigotin je povezan s somnolenco, vključno s prekomerno dnevno somnolenco, in epizodami nenadnega spanca.
There is no relevant use of Leganto in the paediatric population in Parkinson's disease. 
Zdravilo Leganto ni primerno za uporabo pri pediatrični populaciji s Parkinsonovo boleznijo.
You may find it helpful to tell a member of your family or carer that you are using this medicine and ask them to read this leaflet. 
Morda vam bo v pomoč, če poveste družinskemu članu ali negovalcu, da uporabljate to zdravilo in ga prosite, da prebere to navodilo.
Because therapy with Leganto is initiated at a low dose and gradually titrated according to clinical tolerability to obtain the optimum therapeutic effect, adjustment of the dose based on gender, weight, or age is not necessary. 
Zdravljenje z zdravilom Leganto se začne z majhnim odmerkom, ki se za doseganje optimalnega učinka zdravljenja postopno povečuje glede na klinično toleranco, zato prilagajanje odmerka glede na spol, telesno maso ali starost ni potrebno.
Fibrotic complications 
Fibrotični zapleti
• If the edges of the patch lift, the patch may be taped down with adhesive medical tape. 
• Če se robovi obliža odlepijo, jih lahko zalepite z medicinskim lepilnim trakom.
Caution is advised when treating patients with severe hepatic impairment, which may result in lower rotigotine clearance. 
Previdnost je potrebna pri bolnikih s hudo jetrno okvaro, ki se lahko odraža z manjšim očistkom rotigotina.
Because rotigotine is a dopamine agonist, it is assumed that dopamine antagonists, such as neuroleptics (e.g. phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Leganto, and co-administration should be avoided. 
Rotigotin je agonist dopamina, zato se predpostavlja, da lahko antagonisti dopamina, kot so nevroleptiki (npr. fenotiazini, butirofenoni, tioksanteni) ali metoklopramid, zmanjšajo učinkovitost zdravila Leganto in se je treba njihovi sočasni uporabi izogibati.
Leganto can cause side effects that change your behaviour (how you act). 
Zdravilo Leganto lahko povzroči neželene učinke in spremeni vaše vedenje (obnašanje).
The improved room temperature patch formulation showed better skin adhesion than the cold storage formulation with >90% of patches showing sufficient adhesion (i.e. >70% of the patch area adhering) compared to <83%. 
Obliž, ki se ga shranjuje na sobni temperaturi, je imel boljši oprejem na koži kot obliž, ki se ga shranjuje na hladnem, saj je > 90 % obližev, ki se jih shranjuje na sobni temperaturi, imelo zadosten oprijem (to je > 70 % površine obliža oprijete) v primerjavi z < 83 % obližev, ki se jih shranjuje na hladnem.
Rotigotine has been associated with somnolence and episodes of sudden sleep onset. 
Rotigotin je povezan s somnolenco in epizodami nenadnega spanca.
The patches of 2 mg/24 h are used for the treatment of Parkinson´s disease and Restless Leg Syndrome. 
Obliži jakosti 2 mg/24 h se uporabljajo za zdravljenje Parkinsonove bolezni in sindroma nemirnih nog.
After removal, the used patch should be folded in half, adhesive side inwards so that the matrix layer is not exposed, placed in the original sachet and then discarded. 
Po odstranitvi je treba obliž prepogniti na pol, z lepljivo plastjo navznoter, tako da matriksna plast ni izpostavljena, ga dati v originalno zaščitno vrečko in nato odstraniti.
Because rotigotine decreases prolactin secretion in humans, inhibition of lactation is expected. 
Rotigotin zmanjša izločanje prolaktina pri človeku, zato je pričakovano zaviranje laktacije.
What Leganto is and what it is used for 
Kaj je zdravilo Leganto in za kaj ga uporabljamo
• stomach discomfort and pain 
• neprijeten občutek v želodcu in bolečina
Patients not taking levodopa - early stage of Parkinson's disease 
Bolniki, ki ne jemljejo levodope - zgodnja faza Parkinsonove bolezni
• If you have forgotten to stick on a new patch after removing the old one, use a new patch as soon as you remember. 
• Če ste po odstranitvi starega obliža pozabili namestiti novega, ga namestite takoj, ko se spomnite.
The dose of Leganto will depend on your illness - see below. 
Odmerek zdravila Leganto bo odvisen od vaše bolezni - glejte spodaj.
The backing layer of Leganto contains aluminium. 
Oporna plast obliža zdravila Leganto vsebuje aluminij.
After 6 months of maintenance treatment in patients with moderate to severe RLS, the baseline IRLS score improved from 30.7 to 20.7 for placebo and from 30.2 to 13.8 for rotigotine. 
Po 6 mesecih vzdrževalnega zdravljenja so se pri bolnikih z zmerno do hudo obliko RLS vrednosti IRLS izboljšale iz 30,7 na 20,7 za placebo in iz 30,2 na 13,8 za rotigotin.
Open the sachet. 
Odprite zaščitno vrečko.
• your eyes need checking regularly while using Leganto. 
• potrebujete redne okulistične preglede med uporabo zdravila Leganto.
Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of Parkinson's disease and Restless Legs Syndrome. 
Rotigotin je neergolinični agonist dopamina za zdravljenje znakov in simptomov Parkinsonove bolezni in sindroma nemirnih nog.
Steady-state concentrations are reached after one to two days of patch application and are maintained at a stable level by once daily application in which the patch is worn for 24 hours. 
Koncentracije v stanju dinamičnega ravnovesja se dosežejo po enem dnevu do dveh dnevih po namestitvi obliža in se vzdržujejo na stabilni ravni z vsakodnevno namestitvijo novega obliža, ki ga bolnik nosi 24 ur.
These events have also been observed during treatment with rotigotine, but the incidence was similar to that observed in placebo-treated patients. 
Ta pojav so opazili tudi pri zdravljenju z rotigotinom, vendar je bila incidenca podobna kot pri bolnikih, ki so prejemali placebo.
• increased sex drive 
• povečana spolna sla
• Do not let the area of the patch get hot - for example too much sunlight, saunas, hot baths, heating pads or hot-water bottles. 
• Ne pustite, da se površina obliža segreje - na primer zaradi pretiranega sončenja, savn, vročih kopeli, uporabe ogrevalnih blazin ali termoforjev.
Improvements in the mean PDSS-2 total score were 5.9 (rotigotine, baseline 19.3) and 1.9 points (placebo, baseline 20.5). 
Izboljšanje srednjih vrednosti rezultatov PDSS-2 je bilo za 5,9 točk (rotigotin, izhodiščna vrednost 19,3) in za 1,9 točk (placebo, izhodiščna vrednost 20,5).
These include: 
To vključuje:
• If the patch has irritated your skin, keep that area protected from direct sunlight. 
• Če obliž razdraži kožo, to mesto na koži zaščitite pred direktno sončno svetlobo.
Magnetic resonance imaging and cardioversion 
Magnetnoresonančno slikanje in kardioverzija
In subjects with moderate hepatic impairment or mild to severe renal impairment, no relevant increases of rotigotine plasma levels were observed. 
Pri bolnikih z zmerno jetrno okvaro ali blago do hudo ledvično okvaro niso opazili pomembnih povečanj ravni rotigotina v plazmi.
Abnormal thinking and behaviour have been reported and can consist of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behaviour, disorientation, aggressive behaviour, agitation, and delirium. 
Poročali so o nenormalnem mišljenu in vedenju, ki se lahko kaže z različnimi znaki, vključno s paranoidnimi mislimi, blodnjami, halucinacijami, zmedenostjo, psihotičnim vedenjem, dezorientiranostjo, agresivnim vedenjem, agitiranostjo in delirijem.
Leganto is available in different strength patches which release the medicine over 24 hours. 
Zdravilo Leganto je na voljo v različnih jakostih obližev, vsak sprosti različno količino učinkovine v 24 urah.
Rotigotine is metabolised by N-dealkylation as well as direct and secondary conjugation. 
Njegova presnova poteka z N-dealkilacijo ter z neposredno in s sekundarno konjugacijo.
Do not use Leganto if you are pregnant. 
Ne jemljite zdravila Leganto, če ste noseči.
The most likely adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions and other signs of central dopaminergic stimulation. 
Najverjetnejši neželeni učinki bi lahko bili povezani s farmakodinamičnim profilom agonistov dopamina, vključno z navzeo, bruhanjem, hipotenzijo, nehotenimi gibi, halucinacijami, zmedenostjo, konvulzijami in drugimi znaki osrednje dopaminergične stimulacije.
Improvements were seen in UPDRS Parts I - IV scores. 
V študiji je bilo vidno izboljšanje rezultatov v UPDRS delih od I do IV.
• redness, increased sweating 
• rdečina, povečano znojenje
• The patches should not be cut into pieces. 
• Obližev se ne sme rezati na koščke.
Sudden onset of sleep and somnolence 
Nenaden spanec in somnolenca
If you think that too much heat has been applied, contact your doctor or pharmacist. 
Če menite, da je bilo uporabljeno preveč toplote, se posvetujte z zdravnikom ali farmacevtom.
Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists (see also section 4.5). 
Bolnikom, ki jemljejo agoniste dopamina, se proti bruhanju ne sme dajati nevroleptikov (glejte tudi poglavje 4.5).
Retinal degeneration was not observed during the routine histopathological evaluation of the eyes in any of the toxicology studies in any species used. 
Pri rutinskih histopatoloških pregledih oči pri nobeni toksikološki študiji na nobeni živalski vrsti niso opazili razpada mrežnice.
Observed in 2011 data pool of double-blind placebo-controlled studies 
Opaženo v bazi podatkov dvojno slepe s placebom nadzorovane študije iz leta 2011
This can happen especially when you start using Leganto or when your dose is increased. 
To se lahko zgodi zlasti na začetku zdravljenja z zdravilom Leganto ali ob povečanju odmerka.
Where to stick the patch 
Kam namestiti obliž
Malignant tumours were noted predominantly in the uterus of mid- and high-dose females. 
Maligne tumorje so najpogosteje opazili v maternici samic, ki so prejemale srednje in velike odmerke.
If you experience these symptoms after beginning treatment with Leganto, contact your doctor. 
Če imate te simptome po začetku zdravljenja z zdravilom Leganto, obvestite svojega zdravnika.
• You may get redness and itching on the skin where the patch has been - these reactions are usually mild or moderate. 
• Na mestu, kjer je bil nameščen obliž lahko pride do rdečice in srbenja - te kožne reakcije so navadno blage ali zmerne.
After use the patch still contains active substance. 
Obliž po uporabi še vedno vsebuje zdravilno učinkovino.
A reduction of dosage or termination of therapy should be carefully considered. 
Treba je razmisliti o zmanjšanju odmerka ali prekinitvi zdravljenja.
• Restless Legs Syndrome - lowered by 1 mg every other day. 
• Sindrom nemirnih nog - zmanjšati za 1 mg vsak drug dan.
Main metabolites are sulfates and glucuronide conjugates of the parent compound as well as N-desalkyl-metabolites, which are biologically inactive. 
Glavni presnovki so sulfati in konjugati glukuronida izvirne spojine ter tudi presnovki po dealkilaciji, ki biološko niso aktivni.
Only observed in Parkinson's disease patients Both indications 
Opaženo le pri bolnikih s Parkinsonovo boleznijo Obe indikaciji
• feeling weak (fatigue), feeling tired 
• občutek šibkosti (izčrpanost), občutek utrujenosti
Early morning motor function, assessed by UPDRS part III, and nocturnal sleep disturbances, measured by the modified Parkinson's Disease Sleep Scale (PDSS-2), were co-primary outcome measures. 
Primarni merili za oceno izida sta bili motorična funkcija zgodaj zjutraj, ocenjena z lestvico UPDRS III. del, in motnje nočnega spanja, merjene s spremenjeno lestvico spanja pri bolnikih s Parkinsonovo boleznijo (PDSS-2).
Approximately 45% of the active substance within the patch is released to the skin in 24 hours. 
V 24 urah se iz obliža v kožo sprosti približno 45 % zdravilne učinkovine.
If the patch falls off, put on a new patch for the rest of the day - then replace the patch at the usual time. 
Če obliž odpade, namestite nov obliž za preostanek dneva, nato zamenjajte obliž ob istem času kot ponavadi.
To prevent the patch becoming loose or falling off 
Da bi preprečili zrahljanje obliža in njegovo odlepitev
Leganto contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people. 
Sulfit lahko povzroči alergijski tip reakcij, ki pri občutljivih ljudeh vključujejo simptome anafilaksije in življensko ogrožujoče ali manj hude epizode astme.
Peripheral oedema has also been observed in clinical trials conducted in patients with RLS. 
Periferni edem so opazili tudi v kliničnih preskušanjih pri bolnikih z RLS.
Treatment differences for the coprimary variables were statistically significant (p=0.0002 and p<0.0001). 
Razlike med zdravljenjima glede na primarne spremenljivke so bile statistično pomembne (p=0,0002 in p<0,0001).
To avoid skin irritation 
Da bi preprečili draženje kože
• you may get skin problems caused by the patch - see ‘Skin problems caused by the patch' in section 4. 
• lahko dobite kožne reakcije, ki jih povzroči obliž - glejte ‘Kožne reakcije, povzročene z obližem' v poglavju 4.
Switching to rotigotine was feasible, with minor dose adjustment (median 2 mg/24 h) being necessary in only 2 patients switching from ropinirole, 5 patients from pramipexole and 4 patients from cabergoline. 
Ob zamenjavi na rotigotin je bila manjša prilagoditev odmerka (mediana 2 mg/24 ur) potrebna le pri 2 bolnikih, ki so se zdravili z ropinirolom, 5 bolnikih s pramipeksolom in 4 bolnikih, ki so prejemali kabergolin.
In such cases, contact your doctor or hospital straight away. 
V teh primerih takoj obvestite svojega zdravnika ali bolnišnico, kjer vam bodo dali nadaljnja navodila.
Each pack of 28 transdermal patches for a 4 week treatment schedule contains: 7 transdermal patches of Leganto 2 mg/24 h 
Vsako pakiranje z 28 transdermalnimi obliži za 4-tedenski razpored zdravljenja vsebuje: 7 transdermalnih obližev Leganto 2 mg/24 h
Thin, matrix-type, square-shaped with rounded edges, consisting of three layers. 
Tanek, matriksni, kvadratni obliž z zaobljenimi robovi, sestavljen iz treh plasti.
4 mg/24 h may be an effective dose in some patients. 
4 mg/24 h lahko zadošča kot učinkovit odmerek za nekatere bolnike.
In vitro results indicate that different CYP isoforms are able to catalyse the N-dealkylation of rotigotine. 
Rezultati in vitro kažejo, da N-dealkilacijo rotigotina lahko katalizirajo različne izooblike CYP.
Sleep (PDSS) improved by 4.1 ± 13.8 points for rotigotinetreated patients, and by 2.5 ± 13.5 points for ropinirole-treated patients. 
Spanje (PDSS) je bilo izboljšano za 4,1 ± 13,8 točk pri bolnikih zdravljenih z rotigotinom in 2,5 ± 13,5 točk pri bolnikih zdravljenih z ropinirolom.
• falling. 
• padci.
Adjustment of the dose is not necessary in patients with mild to severe renal impairment, including those requiring dialysis. 
Prilagajanje odmerka pri bolnikih z blago do hudo ledvično okvaro, vključno z bolniki, ki potrebujejo dializo, ni potrebno.
What Leganto is and what it is used for What you need to know before you use Leganto How to use Leganto 
Kaj je zdravilo Leganto in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Leganto Kako uporabljati zdravilo Leganto Možni neželeni učinki
The discontinuation rate was studied in 3 clinical trials ranging up to 3 years in duration. 
V 3 kliničnih preskušanjih so raziskovali delež prekinitev zdravljenja v časovnem obdobju do 3 let.
Rotigotine was not teratogenic in all three species, but was embryotoxic in rats and mice at materno-toxic doses. 
Rotigotin pri nobeni izmed teh vrst ni bil teratogen, vendar je bil pri odmerkih, ki so bili toksični za mater pri podganah in miših, embriotoksičen.
In the absence of human data, breast-feeding should be discontinued. 
Zaradi pomanjkanja podatkov pri človeku naj bi dojenje med zdravljenjem prekinili.
Fold back the other half of the patch and remove the other side of the release liner. 
Drugo polovico obliža prepognite nazaj in odstranite še drugo stran zaščitne plasti.
The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson's patients. 
Incidenca nekaterih dopaminergičnih neželenih učinkov, kot so halucinacije, diskinezija in periferni edem, je na splošno večja pri uporabi v kombinaciji z L-dopo pri bolnikih s Parkinsonovo boleznijo.
The Leganto treatment initiation pack contains 4 different packages (one for each strength) with 7 patches in each package. 
Pakiranje za začetno zdravljenje z zdravilom Leganto vsebuje 4 različna pakiranja (po eno za vsako jakost) s 7 obliži v vsakem pakiranju.
Disturbances in consciousness NEC 
glavobol motnje zavesti NEC
With nondopaminergic receptors, rotigotine showed antagonism at alpha2B and agonism at 5HT1A receptors, but no activity on the 5HT2B receptor. 
Pri nedopaminergičnih receptorjih ima rotigotin antagonistično delovanje na receptorje α 2B in agonistično delovanje na receptorje 5HT1A, na 5HT2B receptorje pa ne deluje.